Earlier this month, Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins. The company also revealed the expansion of its Insulin Value Program, which limits patient out-of-pocket costs to $35 or less per month. The move will significantly help Americans with difficulty steering a convoluted healthcare system that may keep them from getting affordable insulin.
In this clip, Karen Hunter discusses the impact of the price reduction with Danielle Hairston, who details her journey with diabetes.
To listen to the full three-hour radio show, get the @siriusxm app and search “Karen Hunter Show.” Free Trial: https://care.siriusxm.com/subscribe/c…
